Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Pharmaceuticals / Appetite suppressants

280 In the index

Rimonabant RIMO

A weight-loss drug that was approved in Europe (Acomplia) before being pulled from the market everywhere. Human trials confirmed it really did cause weight loss, but it also significantly raised the risk of depression and suicidal thoughts, which led regulators to withdraw it entirely.

Also known as Acomplia

Effects Lose fat
Routes Oral
Legal status Unapproved / investigational
WADA Not listed

3D Molecular Structure of C22H21Cl3N4O

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Chlorine
  • Nitrogen
  • Oxygen

Chemistry

Formula
C22H21Cl3N4O
Molar mass
463.8
CAS
168273-06-1
PubChem CID
104850

Reported dosing

Limited data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 20 mg/day (as approved outside the US, before withdrawal)
Reported range 5-20 mg/day
Route Oral
Frequency Once daily
Duration Was intended for chronic use before market withdrawal

A CB1 receptor antagonist approved in Europe (as Acomplia) for weight loss but never approved in the US and withdrawn globally in 2009 after being linked to severe depression and suicidal ideation.

Where this comes from European prescribing information (withdrawn); post-marketing safety data

Human data for this compound is limited. Read the figures above as a record of reported use rather than established dosing.